{"id":201993,"date":"2018-09-19T19:00:12","date_gmt":"2018-09-19T13:30:12","guid":{"rendered":"https:\/\/www.scconline.com\/blog\/?p=201993"},"modified":"2018-09-21T15:58:54","modified_gmt":"2018-09-21T10:28:54","slug":"improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside","status":"publish","type":"post","link":"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/","title":{"rendered":"Improved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside"},"content":{"rendered":"

Delhi High Court:<\/strong> A Single Judge Bench comprising of Vibhu Bakhru, J. allowed a writ petition filed against the order of National Pharmaceuticals Pricing Authority (NPPA) demanding a sum of Rs 86,66,045.<\/p>\n

The said demand was founded on the basis that the petitioner INTAS has sold its CEFTAS 400 tablets at a price in excess of ceiling price fixed for CEFIXIME 400 mg tablets which are included in Schedule I to Drugs (Price Control) Order, 2013. The petitioner claimed that even though CEFTAS contains CEFIXIME, it is not included in Schedule I and is not a scheduled formulation<\/em>. It is so because CEFTAS is a dispersible tablet which is a novel formulation <\/em>completely distinct and separate from conventional CEFIXIME tablet. The question before the Court was whether CEFTAS is included in Schedule I to DPCO 2013.<\/p>\n

The High Court perused Paragraph 8(1) DPCO which provides what is a maximum retail price<\/em>; sub-clause (zb) of Paragraph 2(1) which defines a scheduled formulation<\/em>. It was observed that principal objective of the National Pharmaceuticals Pricing Policy, 2012 is to put in place a regulatory framework for pricing of drugs so as to ensure availability of essential medicines at reasonable prices. Reference was also made Explanation (2) to Schedule I titled Innovation in medicines must be encouraged<\/em>. In the opinion of the Court, it was apparent from the explanation that improved formulations developed through incremental innovation involving technology for overcoming disadvantages associated with conventional forms would not be read as included in the National List of Essential Medicines, 2015 which is appended to Schedule I of DPCO 2013. On a plain reading of the order impugned, the Court held that NPPA proceeded on the basis that irrespective of the incremental innovation or the novelty of drug delivery system, all versions of the formulations would be included. The contention was erroneous and unsustainable. As such, the Court set aside the order impugned and directed NPPA to examine whether the different delivery system, as claimed by INTAS, was a substantial improvement with significant therapeutic advantages so as to consider the product materially different from a conventional version. The petition was disposed of in the terms above. [INTAS Pharmaceuticals Ltd. v. Union of India, 2018 SCC OnLine Del 11328<\/b><\/a>, dated 17-09-2018]<\/p>\n","protected":false},"excerpt":{"rendered":"

Delhi High Court: A Single Judge Bench comprising of Vibhu Bakhru, J. allowed a writ petition filed against the order of National <\/p>\n","protected":false},"author":8808,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3,10],"tags":[31824,31826,31823,31825],"class_list":["post-201993","post","type-post","status-publish","format-standard","hentry","category-casebriefs","category-highcourts","tag-ceftas-400","tag-medicines","tag-national-pharmaceuticals-pricing-authority","tag-scheduled-formulation"],"yoast_head":"\nImproved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside | SCC Times<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Improved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside\" \/>\n<meta property=\"og:description\" content=\"Delhi High Court: A Single Judge Bench comprising of Vibhu Bakhru, J. allowed a writ petition filed against the order of National\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/\" \/>\n<meta property=\"og:site_name\" content=\"SCC Times\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/scc.online\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-19T13:30:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-09-21T10:28:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/10\/Delhi-HC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1329\" \/>\n\t<meta property=\"og:image:height\" content=\"888\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Bhumika Indulia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bhumika Indulia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/\",\"name\":\"Improved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside | SCC Times\",\"isPartOf\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\"},\"datePublished\":\"2018-09-19T13:30:12+00:00\",\"dateModified\":\"2018-09-21T10:28:54+00:00\",\"author\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.scconline.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Improved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\",\"url\":\"https:\/\/www.scconline.com\/blog\/\",\"name\":\"SCC Times\",\"description\":\"Bringing you the Best Analytical Legal News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.scconline.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a\",\"name\":\"Bhumika Indulia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg\",\"contentUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg\",\"caption\":\"Bhumika Indulia\"},\"url\":\"https:\/\/www.scconline.com\/blog\/post\/author\/editor_1\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Improved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside | SCC Times","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/","og_locale":"en_US","og_type":"article","og_title":"Improved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside","og_description":"Delhi High Court: A Single Judge Bench comprising of Vibhu Bakhru, J. allowed a writ petition filed against the order of National","og_url":"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/","og_site_name":"SCC Times","article_publisher":"https:\/\/www.facebook.com\/scc.online\/","article_published_time":"2018-09-19T13:30:12+00:00","article_modified_time":"2018-09-21T10:28:54+00:00","og_image":[{"width":1329,"height":888,"url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/10\/Delhi-HC.jpg","type":"image\/jpeg"}],"author":"Bhumika Indulia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Bhumika Indulia","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/","url":"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/","name":"Improved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside | SCC Times","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/#website"},"datePublished":"2018-09-19T13:30:12+00:00","dateModified":"2018-09-21T10:28:54+00:00","author":{"@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a"},"breadcrumb":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.scconline.com\/blog\/post\/2018\/09\/19\/improved-formulations-developed-through-incremental-innovation-not-to-be-included-in-schedule-i-to-dpco-2013-nppa-decision-to-include-ceftas-400-set-aside\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.scconline.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Improved formulations developed through incremental innovation not to be included in Schedule I to DPCO 2013; NPPA decision to include CEFTAS 400 set aside"}]},{"@type":"WebSite","@id":"https:\/\/www.scconline.com\/blog\/#website","url":"https:\/\/www.scconline.com\/blog\/","name":"SCC Times","description":"Bringing you the Best Analytical Legal News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.scconline.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a","name":"Bhumika Indulia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg","contentUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg","caption":"Bhumika Indulia"},"url":"https:\/\/www.scconline.com\/blog\/post\/author\/editor_1\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":185074,"url":"https:\/\/www.scconline.com\/blog\/post\/2018\/01\/31\/national-pharmaceutical-pricing-authority-eases-norms-new-drug-approvals\/","url_meta":{"origin":201993,"position":0},"title":"National Pharmaceutical Pricing Authority eases norms for new drug approvals","author":"Saba","date":"January 31, 2018","format":false,"excerpt":"After a major slowdown, new drug approvals are likely to pick up after the National Pharmaceutical Pricing Authority (NPPA) decided to de-link price approval of new drugs with its internal guidelines, a move seen as a major relief to pharmaceutical companies. NPPA says in office memorandum that price approval of\u2026","rel":"","context":"In "Business News"","block_context":{"text":"Business News","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/business_news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/05\/Drugs.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/05\/Drugs.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/05\/Drugs.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/05\/Drugs.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/05\/Drugs.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":307301,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/11\/16\/delhi-high-court-did-not-interfere-overcharge-drug-formulation-national-pricing-authority-legal-news\/","url_meta":{"origin":201993,"position":1},"title":"Delhi High Court| Increasing MRP of non-scheduled formulation to maximum permissible increase of 10% in a year not necessary","author":"Arunima","date":"November 16, 2023","format":false,"excerpt":"The 10% increase in MRP permissible under Para 20 of Drugs (Price Control) Order, 2013 must be calculated based on the actual MRP of the non-scheduled formulation in the preceding twelve months and not based on what was the MRP permissible for the preceding twelve months.","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"delhi high court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/10\/delhi-high-court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/10\/delhi-high-court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/10\/delhi-high-court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/10\/delhi-high-court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":114371,"url":"https:\/\/www.scconline.com\/blog\/post\/2017\/03\/15\/mandatory-for-hospitals-to-issue-detailed-bills-to-patients-separately-disclosing-cost-of-coronary-stents\/","url_meta":{"origin":201993,"position":2},"title":"Mandatory for Hospitals to issue detailed bills to patients, separately disclosing cost of Coronary Stents","author":"Saba","date":"March 15, 2017","format":false,"excerpt":"Minister of State for Chemicals & Fertilizers, Road Transport & Highways and Shipping, Shri Mansukh L. Mandaviya, while giving a written reply to a question in Lok Sabha on 14-3-2017, said that the National Pharmaceuticals Pricing Authority (NPPA), under Ministry of Chemicals & Fertilizers, has directed hospitals to issue detailed\u2026","rel":"","context":"In "Hot Off The Press"","block_context":{"text":"Hot Off The Press","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/hot_off_the_press\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":107161,"url":"https:\/\/www.scconline.com\/blog\/post\/2017\/02\/17\/coronary-stent-prices-capped-to-bring-down-cost-currently-hiked-by-about-380\/","url_meta":{"origin":201993,"position":3},"title":"Coronary Stent Prices capped, to bring down cost, currently hiked by about 380%","author":"Saba","date":"February 17, 2017","format":false,"excerpt":"Pursuing Prime Minister's vision of Affordable, Quality Healthcare for All, Government of India has issued the notification for fixing the ceiling prices of coronary stents, informed Union Minister for Chemicals & Fertilizers and Parliamentary Affairs, Shri Ananthkumar. The step would bring down the cost of coronary stents,currently hiked by about\u2026","rel":"","context":"In "Hot Off The Press"","block_context":{"text":"Hot Off The Press","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/hot_off_the_press\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2015\/12\/DSC_4762-e1474523869607.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":250246,"url":"https:\/\/www.scconline.com\/blog\/post\/2021\/06\/24\/oxygen-and-the-pandemic-faqs-for-corporates\/","url_meta":{"origin":201993,"position":4},"title":"Oxygen and the Pandemic: FAQs for Corporates","author":"Bhumika Indulia","date":"June 24, 2021","format":false,"excerpt":"by Shantanu Mukherjee\u2020 Cite as: 2021 SCC OnLine Blog Exp 50","rel":"","context":"In "Op Eds"","block_context":{"text":"Op Eds","link":"https:\/\/www.scconline.com\/blog\/post\/category\/op-ed\/legal-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/06\/MicrosoftTeams-image-43.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/06\/MicrosoftTeams-image-43.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/06\/MicrosoftTeams-image-43.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/06\/MicrosoftTeams-image-43.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/06\/MicrosoftTeams-image-43.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":279236,"url":"https:\/\/www.scconline.com\/blog\/post\/2022\/12\/07\/karnataka-hc-healthcare-global-enterprises-loss-of-profit-due-to-price-regularisation-of-essential-anti-cancer-drugs-is-not-a-ground-for-judicial-review-of-a-government-policy\/","url_meta":{"origin":201993,"position":5},"title":"Karnataka HC | Healthcare Global Enterprises\u2019 loss of profit due to price regularisation of essential anti-cancer drugs, is not a ground for judicial review of a Government Policy","author":"Editor","date":"December 7, 2022","format":false,"excerpt":"A Government Order regulating, and rationalising prices of essential anti-cancer drugs was challenged before the Karnataka HC. The Court clearly stated that the challenge vis-a-vis petitioner's loss of profit, cannot be sustained","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"Karnataka High Court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2022\/11\/Karnataka-High-Court-2-1.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/201993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/users\/8808"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/comments?post=201993"}],"version-history":[{"count":0,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/201993\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media?parent=201993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/categories?post=201993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/tags?post=201993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}